177Lu-DOTA-IBA Therapy in Prostate Cancer With Bone Metastases

Article Radiology, Nuclear Medicine & Medical Imaging

Safety and Efficacy of 68Ga- or 177Lu-Labeled DOTA-IBA as a Novel Theranostic Radiopharmaceutical for Bone Metastases A Phase 0/I Study

Lin Qiu et al.

Summary: This study evaluated the efficacy, safety, and dosimetry of a novel theranostic radiopharmaceutical (Ga-68- or Lu-177-labeled DOTA-ibandronic acid) for bone metastasis. Ga-68-DOTA-IBA PET showed higher efficacy than Tc-99m-MDP SPECT in detecting bone metastases. Lu-177-DOTA-IBA therapy had no significant effect on bone marrow hematopoietic function, liver function, and kidney function, and achieved bone pain palliation in 82% of patients.

CLINICAL NUCLEAR MEDICINE (2023)

添加到收藏夹

Article Medicine, Research & Experimental

Lutetium177-Labeled DOTA-Ibandronate: A Novel Radiopharmaceutical for Targeted Treatment of Bone Metastases

Qixin Wang et al.

Summary: A new bisphosphonate radiopharmaceutical, Lu-177-DOTA-IBA, was synthesized and studied for targeted diagnosis and treatment of bone metastases. It exhibited good biological properties and safety, with promising results in a preliminary clinical translation study.

MOLECULAR PHARMACEUTICS (2023)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Utility of PET to Appropriately Select Patients for PSMA-Targeted Theranostics

Anna Eshghi et al.

Summary: PSMA is an attractive target for drug development in aggressive prostate cancers. Numerous PSMA-targeted radiopharmaceuticals have been developed for imaging and therapy. PSMA PET provides a method to better select patients for PSMA-targeted therapy, and ongoing clinical trials are studying PSMA-targeted therapeutic agents. PET parameters using PSMA and FDG PET/CT have been investigated as predictive and prognostic biomarkers. This article discusses the optimal use of PET for patient selection and provides an overview of choice of PET tracer, targeting molecule, therapeutic radioisotope, nonradioactive therapy, and cancer type.

CLINICAL NUCLEAR MEDICINE (2022)

添加到收藏夹

Article Oncology

Preparation, biological characterization and preliminary human imaging studies of 68Ga-DOTA-IBA

Yingwei Wang et al.

Summary: This study radiolabeled DOTA-IBA with Ga-68, assessed its distribution in animals and imaging in humans, and explored its potential as a bone imaging agent. Ga-68-DOTA-IBA demonstrated high purity, good biological properties, and potential for novel bone imaging modalities.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Evaluation of Safety and Dosimetry of 177Lu-DOTA-ZOL for Therapy of Bone Metastases

Rene Fernandez et al.

Summary: The study evaluated the safety and dosimetry of a new therapeutic radiopharmaceutical, 177Lu-DOTA-ZOL, for bone metastasis through a series of SPECT/CT images and blood samples. Results showed fast uptake and high retention in bone lesions, with a stable average retention rate in tumor lesions after injection. The red marrow was identified as the dose-limiting organ for all patients, suggesting personalized dosimetry should be considered to prevent severe hematotoxicity.

JOURNAL OF NUCLEAR MEDICINE (2021)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Comparing 99mTc-PSMA to 99mTc-MDP in Prostate Cancer Staging of the Skeletal System

Joseph Kabunda et al.

Summary: This prospective study found that Tc-99m-PSMA scan was comparable to Tc-99m-MDP in detecting bone metastases, but provided additional information on lymph nodal metastases and residual disease in prostate. Equivocal findings were reported in 4 patients on Tc-99m-MDP and none on Tc-99m-PSMA.

CLINICAL NUCLEAR MEDICINE (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology